Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This review discusses the management of adverse events associated with sacituzumab govitecan use in real-world settings and provides no new clinical results; it emphasizes practical strategies for clinicians treating breast cancer patients.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.